Checkpoint Inhibition Prior to Stem Cell Transplantation Increases the Risk of Inflammatory Adverse Events.

IF 4 3区 医学 Q2 ONCOLOGY Targeted Oncology Pub Date : 2025-03-01 Epub Date: 2025-02-04 DOI:10.1007/s11523-025-01127-7
Malek Shatila, Antonio Pizuorno Machado, Jay Shah, Andres Urias Rivera, Sidra Naz, Stephen Glombicki, Sharada Wali, Eric Lu, Nicholas Short, Anusha Thomas, Hao Chi Zhang, Yinghong Wang
{"title":"Checkpoint Inhibition Prior to Stem Cell Transplantation Increases the Risk of Inflammatory Adverse Events.","authors":"Malek Shatila, Antonio Pizuorno Machado, Jay Shah, Andres Urias Rivera, Sidra Naz, Stephen Glombicki, Sharada Wali, Eric Lu, Nicholas Short, Anusha Thomas, Hao Chi Zhang, Yinghong Wang","doi":"10.1007/s11523-025-01127-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Stem cell transplantation (SCT) and immune checkpoint inhibitors (ICIs) are both used in the treatment of hematological malignancies. There may be an overlap in patient exposure to both treatments. Theoretically, ICIs potentiate the graft-versus-tumor effect following SCT but may increase the risk of inflammatory adverse events (AEs). Conversely, immunosuppression following SCT may decrease the risk of immune-mediated AEs.</p><p><strong>Objectives: </strong>We aimed to explore the effect of immunotherapy on the risk and severity of inflammatory AEs following SCT.</p><p><strong>Patients and methods: </strong>We performed a single-center, retrospective chart review that included all patients with a hematological malignancy treated with immunotherapy and who received SCT. Patients who did not receive immunosuppressive regimens after their transplant (e.g., autologous transplants) were excluded. Patients were divided into two groups based on ICI timing: pre-SCT ICI (group 1) and post-SCT ICI (group 2).</p><p><strong>Results: </strong>A total of 63 patients were included. Around 82% of patients in group 1 experienced a post-transplant AE compared with 50% in group 2 (p = 0.014). These AEs occurred earlier in group 1 patients (median 57 days in group 1 versus 195 in group 2; p = 0.007). Roughly 80% of the inflammatory conditions involved the gastrointestinal system. Severity and complication rates did not differ between groups, but gastrointestinal inflammation in group 1 was more likely to require immunosuppressive medication (75.7% and 37.8% requiring corticosteroids and selective immunosuppressive therapy, respectively, in group 1 patients versus 33.3% and 0% in group 2 patients; p < 0.05).</p><p><strong>Conclusion: </strong>To our knowledge, our study is one of few exploring the impact of ICI timing in relation to SCT on the risk of post-SCT inflammatory AEs. Administration of immunotherapy prior to SCT may predispose patients to inflammatory AEs after SCT, which may occur earlier and last longer than if ICIs are started after SCT. Future studies are needed to further explore this phenomenon.</p>","PeriodicalId":22195,"journal":{"name":"Targeted Oncology","volume":" ","pages":"329-337"},"PeriodicalIF":4.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Targeted Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11523-025-01127-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Stem cell transplantation (SCT) and immune checkpoint inhibitors (ICIs) are both used in the treatment of hematological malignancies. There may be an overlap in patient exposure to both treatments. Theoretically, ICIs potentiate the graft-versus-tumor effect following SCT but may increase the risk of inflammatory adverse events (AEs). Conversely, immunosuppression following SCT may decrease the risk of immune-mediated AEs.

Objectives: We aimed to explore the effect of immunotherapy on the risk and severity of inflammatory AEs following SCT.

Patients and methods: We performed a single-center, retrospective chart review that included all patients with a hematological malignancy treated with immunotherapy and who received SCT. Patients who did not receive immunosuppressive regimens after their transplant (e.g., autologous transplants) were excluded. Patients were divided into two groups based on ICI timing: pre-SCT ICI (group 1) and post-SCT ICI (group 2).

Results: A total of 63 patients were included. Around 82% of patients in group 1 experienced a post-transplant AE compared with 50% in group 2 (p = 0.014). These AEs occurred earlier in group 1 patients (median 57 days in group 1 versus 195 in group 2; p = 0.007). Roughly 80% of the inflammatory conditions involved the gastrointestinal system. Severity and complication rates did not differ between groups, but gastrointestinal inflammation in group 1 was more likely to require immunosuppressive medication (75.7% and 37.8% requiring corticosteroids and selective immunosuppressive therapy, respectively, in group 1 patients versus 33.3% and 0% in group 2 patients; p < 0.05).

Conclusion: To our knowledge, our study is one of few exploring the impact of ICI timing in relation to SCT on the risk of post-SCT inflammatory AEs. Administration of immunotherapy prior to SCT may predispose patients to inflammatory AEs after SCT, which may occur earlier and last longer than if ICIs are started after SCT. Future studies are needed to further explore this phenomenon.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
干细胞移植前检查点抑制增加炎症不良事件的风险。
背景:干细胞移植(SCT)和免疫检查点抑制剂(ICIs)都被用于血液系统恶性肿瘤的治疗。患者接受这两种治疗的时间可能有重叠。理论上,ICIs增强了SCT后移植物抗肿瘤效应,但可能增加炎症不良事件(ae)的风险。相反,SCT后的免疫抑制可能会降低免疫介导的ae的风险。目的:我们旨在探讨免疫治疗对SCT后炎症性不良事件的风险和严重程度的影响。患者和方法:我们进行了一项单中心,回顾性图表回顾,包括所有接受免疫治疗的血液恶性肿瘤患者和接受SCT的患者。排除移植后未接受免疫抑制治疗的患者(如自体移植)。根据ICI时间将患者分为两组:sct前ICI(1组)和sct后ICI(2组)。结果:共纳入63例患者。第1组约82%的患者出现移植后AE,而第2组为50% (p = 0.014)。这些不良事件在1组患者中发生得更早(1组为57天,2组为195天;P = 0.007)。大约80%的炎症与胃肠道系统有关。严重程度和并发症发生率在两组之间没有差异,但胃肠道炎症在1组中更可能需要免疫抑制药物(75.7%和37.8%的患者分别需要皮质类固醇和选择性免疫抑制治疗,而在2组中分别为33.3%和0%;P < 0.05)。结论:据我们所知,我们的研究是少数探索与SCT相关的ICI时间对SCT后炎性ae风险影响的研究之一。在SCT之前进行免疫治疗可能使患者在SCT后易发生炎性不良反应,这可能比在SCT后开始免疫治疗更早,持续时间更长。这一现象需要进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Targeted Oncology
Targeted Oncology 医学-肿瘤学
CiteScore
8.40
自引率
3.70%
发文量
64
审稿时长
>12 weeks
期刊介绍: Targeted Oncology addresses physicians and scientists committed to oncology and cancer research by providing a programme of articles on molecularly targeted pharmacotherapy in oncology. The journal includes: Original Research Articles on all aspects of molecularly targeted agents for the treatment of cancer, including immune checkpoint inhibitors and related approaches. Comprehensive narrative Review Articles and shorter Leading Articles discussing relevant clinically established as well as emerging agents and pathways. Current Opinion articles that place interesting areas in perspective. Therapy in Practice articles that provide a guide to the optimum management of a condition and highlight practical, clinically relevant considerations and recommendations. Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement. Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.
期刊最新文献
Revised Recommendations for Restarting Teclistamab Following Dose Delays: Insights from the MajesTEC-1 Study on Clinical Safety, and from Simulated Pharmacokinetics and Cytokine Dynamics. Bispecific Antibodies in Breast Cancer Immunotherapy: Mechanisms, Advances, and Translational Challenges. Evidence for the Monitoring of Minimal Residual Disease Dynamics to Guide Clinical Practice in Patients with Multiple Myeloma. First Things First: Navigating ALK-Positive Metastatic Non-Small Cell Lung Cancer Treatment Options-A Podcast. Age-Related Differences in Severe Adverse Events During Maintenance Therapy with PARP Inhibitors: A Retrospective Cohort Study in Japanese Patients with Ovarian Cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1